Background
Despite high hepatitis B virus (HBV) endemicity in various resource-limited settings (RLS), the impact of maternal HIV-HBV coinfection on infant health outcomes has not been defined.
Method
This study determined the seroprevalence of HBV coinfection among HIV-infected pregnant women enrolled in the India six-week extended-dose nevirapine (SWEN) trial. The impact of maternal HIV-HBV coinfection on MTCT of HIV and infant mortality was assessed using univariate and multivariate logistic regression analysis.
Results
Among 689 HIV-infected pregnant Indian women, 32 (4.6%) had HBV coinfection (95% confidence interval [CI] 3.4, 5.3). HBV DNA was detectable in 18 (64%) of 28 HIV-HBV coinfected women; the median HBV viral load was 155 copies/mL (interquartile range [IQR] < 51–6741). Maternal HIV-HBV coinfection did not increase HIV transmission (adjusted odds ratio [aOR] 1.06, 95% CI 0.30, 3.66; p= 0.93). Increased odds of all-cause infant mortality was noted (aOR 3.12, 95% CI 0.67, 14.57; p=0.15), but was not statistically significant.
Conclusion
The prevalence of active maternal HBV co-infection in HIV-infected pregnant women in India was 4.6%. HIV-HBV coinfection was not independently associated with HIV transmission.